These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 35507051)

  • 21. Detection of clinically significant prostate cancer by transperineal multiparametric magnetic resonance imaging-ultrasound fusion targeted prostate biopsy in smaller prostates.
    Dahl DM; Kim MM; Wu S; Lin SX; Crotty RK; Cornejo KM; Harisinghani MG; Feldman AS; Wu CL
    Urol Oncol; 2022 Oct; 40(10):451.e9-451.e14. PubMed ID: 36008257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing Combined Magnetic Resonance Imaging (MRI)-Targeted and Systematic Biopsy Strategies: Sparing the Multiparametric MRI-Negative Transitional Zone in Presence of Exclusively Peripheral Multiparametric MRI-Suspect Lesions.
    Kachanov M; Leyh-Bannurah SR; Roberts MJ; Sauer M; Beyersdorff D; Boiko S; Maurer T; Steuber T; Graefen M; Budäus L
    J Urol; 2022 Feb; 207(2):333-340. PubMed ID: 34555925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can we omit systematic biopsies in patients undergoing MRI fusion-targeted prostate biopsies?
    Leow JJ; Koh SH; Chow MW; Loke W; Salada R; Hong SK; Yeow Y; Lee CH; Tan CH; Tan TW
    Asian J Androl; 2023; 25(1):43-49. PubMed ID: 35488666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions.
    Fang AM; Shumaker LA; Martin KD; Jackson JC; Fan RE; Khajir G; Patel HD; Soodana-Prakash N; Vourganti S; Filson CP; Sonn GA; Sprenkle PC; Gupta GN; Punnen S; Rais-Bahrami S
    Cancer; 2022 Sep; 128(18):3287-3296. PubMed ID: 35819253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD).
    Falagario UG; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Fossati N; Martini A; Cucchiara V; Picker W; Haug E; Ratnani P; Haines K; Lewis S; Sujit N; Selvaggio O; Sanguedolce F; Macarini L; Cormio L; Nordström T; Tewari A; Briganti A; Boström PJ; Carrieri G
    Eur Urol Oncol; 2021 Dec; 4(6):971-979. PubMed ID: 32972896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the optimal strategy in men with a single unilateral suspicious lesion on MRI undergoing transperineal MRI/ultrasound fusion prostate biopsy.
    Yusim I; Mazor E; Frumkin E; Jabareen M; Hefer B; Elsaraya N; Li S; Rouvinov K; Novack V; Mabjeesh NJ
    Prostate; 2023 Sep; 83(13):1255-1262. PubMed ID: 37263774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Utility of Combined Target and Systematic Prostate Biopsies in the Diagnosis of Clinically Significant Prostate Cancer Using Prostate Imaging Reporting and Data System Version 2 Based on Biparametric Magnetic Resonance Imaging.
    Kato D; Ozawa K; Takeuchi S; Kawase M; Kawase K; Nakai C; Takai M; Iinuma K; Nakane K; Kato H; Matsuo M; Suzui N; Miyazaki T; Koie T
    Curr Oncol; 2021 Mar; 28(2):1294-1301. PubMed ID: 33809967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series.
    Barletta F; Stabile A; Mazzone E; Brembilla G; Sorce G; Pellegrino F; Scuderi S; Cannoletta D; Cirulli GO; Cucchiara V; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
    Urol Oncol; 2022 Mar; 40(3):103.e17-103.e24. PubMed ID: 34688534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Patient and Imaging-Related Factors With False Negative MRI-Targeted Prostate Biopsies of Suspicious PI-RADS 4 and 5 Lesions.
    Movassaghi M; Ahmed F; Patel H; Luk L; Hyams E; Wenske S; Shaish H
    Urology; 2022 Sep; 167():165-170. PubMed ID: 35533767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk-Adapted Strategy Combining Magnetic Resonance Imaging and Prostate-Specific Antigen Density to Individualize Biopsy Decision in Patients With PI-RADS 3 ``Gray Zone'' Lesions.
    Akpinar C; Oz DK; Oktar A; Suer E; Ozden E; Haliloglu N; Gulpinar O; Gokce MI; Gogus C; Baltaci S
    Clin Genitourin Cancer; 2024 Jun; 22(3):102071. PubMed ID: 38555682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A cohort of transperineal electromagnetically tracked magnetic resonance imaging/ultrasonography fusion-guided biopsy: assessing the impact of inter-reader variability on cancer detection.
    Wajswol E; Winoker JS; Anastos H; Falagario U; Okhawere K; Martini A; Treacy PJ; Voutsinas N; Knauer CJ; Sfakianos JP; Lewis SC; Taouli BA; Rastinehad AR
    BJU Int; 2020 Apr; 125(4):531-540. PubMed ID: 31762182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
    Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
    Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Which men with non-malignant pathology at magnetic resonance imaging-targeted prostate biopsy and persistent PI-RADS 3-5 lesions should repeat biopsy?
    Castellani D; Pace G; Cecchini S; Franzese C; Cicconofri A; Romagnoli D; Del Rosso A; Possanzini M; Paci E; Dellabella M; Pierangeli T
    Urol Oncol; 2022 Oct; 40(10):452.e9-452.e16. PubMed ID: 35871992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PI-RADS Upgrading Rules: Impact on Prostate Cancer Detection and Biopsy Avoidance of MRI-Directed Diagnostic Pathways.
    de Oliveira Correia ET; Purysko AS; Paranhos BM; Shoag JE; Padhani AR; Bittencourt LK
    AJR Am J Roentgenol; 2024 May; 222(5):e2330611. PubMed ID: 38353450
    [No Abstract]   [Full Text] [Related]  

  • 37. The Highest Grade Group Does Not Drive the Risk of Recurrence when Systematic and Multiparametric Magnetic Resonance Imaging (MRI)-targeted Biopsies are Discordant: Preliminary Findings Using Radical Prostatectomy Pathology as a Surrogate for MRI-targeted Biopsy Grade.
    Scuderi S; Pellegrino F; Tin A; Beech BB; Gandaglia G; Stabile A; Eastham JA; Montorsi F; Briganti A; Vickers AJ
    Eur Urol Focus; 2024 May; 10(3):486-488. PubMed ID: 37739916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
    Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
    Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An optimized prostate biopsy strategy in patients with a unilateral lesion on prostate magnetic resonance imaging avoids unnecessary biopsies.
    Jager A; van Riel LAMJG; Postema AW; de Reijke TM; van der Sluis TM; Oddens JR
    Ther Adv Urol; 2022; 14():17562872221111410. PubMed ID: 35924207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Analysis of the relationship between PI-RADS scores and the pathological results of targeted biopsy based on MRI].
    Wang YM; Shang JW; Dong L; Liang LH; Zhao RZ; Liang C; Wang SQ; Xia W; Cheng G; Hua LX
    Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):942-947. PubMed ID: 37968079
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.